###### Strengths and limitations of this study

-   The first systematic review and meta-analysis to compare the efficacy of home bilevel positive airway pressure and continuous positive airway pressure therapy in patients with obesity hypoventilation syndrome (OHS).

-   This study will help identify the most appropriate home positive airway pressure therapy strategy for patients with OHS.

-   Only randomised controlled trials, representing a high quality of evidence, will be included in this study.

-   To determine the most appropriate patients to receive bilevel positive airway pressure therapy through subgroup analysis.

Introduction {#s1}
============

The increasing incidence of obesity has become a major concern worldwide.[@R1] Obesity hypoventilation syndrome (OHS) is a major respiratory complication caused by obesity and is characterised by a daytime arterial carbon dioxide pressure (PaCO~2~) \>45 mm Hg with body mass index (BMI) \>30 kg/m^2^ and excluding other causes of hypoventilation (such as neuromuscular disorders, chest wall abnormalities or significant lung diseases.).[@R2] OHS usually appears to be the end consequence of a complex interplay between upper airway obstruction, sleep hypoventilation, decreased lung capacity, increased respiratory muscle load, changing respiratory centre drive and leptin resistance.[@R3] Due to the presence of chronic hypercapnia and hypoxaemia, patients with OHS are at high risk of severe respiratory failure, pulmonary hypertension, chronic cor pulmonale and other cardiovascular complications if not treated appropriately.[@R5] Moreover, this will greatly affect the patient's health-related quality of life, exercise performance and survival rate, and may become a serious social and economic burden.[@R7]

Treatment of this disorder is aimed at improving the pathophysiologic abnormalities of patients with OHS which commonly includes positive airway pressure (PAP) therapy, lifestyle intervention, surgery and pharmacotherapy. PAP therapy is considered to be the first-line treatment, which can effectively improve gas exchange, sleep disorders and survival in patients with OHS.[@R10] Additionally, Castro-Añón *et al* indicated that even with the introduction of PAP therapy, mortality in OHS remains higher than that seen in eucapnic obstructive sleep apnea (OSA) individuals.[@R8] PAP therapy may be delivered as either continuous positive airway pressure (CPAP) or bilevel therapy (including spontaneous (S), timed (T), spontaneous/timed (S/T) or volume-assured pressure support (VAPS) mode). CPAP provides a constant positive pressure in the airway, aiming to reduce upper airway resistance and prevent upper airway obstructive events, thereby controlling sleep disordered breathing and improving oxygenation. However, CPAP is not a truly physiologically based ventilation mode. It simply provides a constant pressure to the airway to maintain the upper airway open and increase lung volumes. In contrast, bilevel therapy provides a differential pressure between inspiration and expiration (pressure support level) which acts to increase tidal volume, improve alveolar hypoventilation and relieve respiratory fatigue.[@R12] Therefore, theoretically bilevel therapy should be more effective in improving oxygenation and reducing arterial carbon dioxide levels than CPAP.

Currently, the optimal mode of home PAP therapy for patients with OHS has not been determined. Only a few randomised controlled trials (RCT)[@R13] but no systematic reviews or meta-analyses have compared the efficacy of domiciliary bilevel versus CPAP therapy in patients with OHS. The main objective of this study is to determine whether bilevel therapy is more effective than CPAP therapy in treating OHS and to identify the best PAP setting for patients with OHS as the first-line treatment.

Objective {#s2}
=========

The goal of this systematic literature review and meta-analysis is to determine the effect of the home bilevel therapy by comparison to CPAP therapy in patients with OHS. Specifically, what is the difference of treatment effect between home bilevel and CPAP therapy in patients with OHS as reported in the research published from January 1980 through November 2017?

Methods {#s3}
=======

This manuscript follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 statement.[@R16]

Eligibility criteria {#s3a}
--------------------

### Study design {#s3a1}

Only RCTs will be included. We will include RCTs comparing the efficiency of domiciliary bilevel and CPAP therapy in patients with OHS.

### Participants {#s3a2}

Only subjects diagnosed with OHS (ie, BMI \>30 kg/m^2^ and daytime PaCO~2~ \>45 mm Hg) with exclusion of other conditions that might lead to hypoventilation including neuromuscular disorders, chest abnormalities or chronic obstructive pulmonary disease will be included in this analysis.[@R2]

### Interventions {#s3a3}

Bilevel therapy, providing a differential pressure between inspiration and expiration, which can increase tidal volume, improve alveolar hypoventilation and relieve respiratory fatigue; CPAP therapy provides a constant positive pressure in the airway, which can reduce upper airway resistance and prevent upper airway obstruction events.[@R12]

### Outcomes {#s3a4}

-   Primary outcome: Daytime PaCO~2~

-   Secondary outcomes:adherence (whether average PAP therapy use of ≥4 hours per night)[@R17]health-related quality of life (the Medical Outcomes Study 36-Item Short-Form Health Survey,[@R19] Epworth Sleepiness Scale,[@R20] Severe Respiratory Insufficiency Questionnaire[@R21])mortalitythe incidence of hospital readmissionslung function[@R22]physical activity (6 min walk test[@R23]).

Information sources and search strategy {#s3b}
---------------------------------------

### Electronic searches {#s3b1}

We will search the following databases: PubMed, Web of Science, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, and CINAHL. The searching period will be from January 1980 to November 2017. Literature retrieved will be limited to human subjects and language or publication status will not be limited. The searches will be reworked before the final analyses, and further studies will also be reviewed for the inclusion. The detailed search strategy of PubMed is presented in online [supplementary file 1](#SP1){ref-type="supplementary-material"}.
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### Searching other resources {#s3b2}

Ongoing studies will be identified through the ClinicalTrials.gov (November 2017) and WHO International Clinical Trials Registry Platform Search Portal (<http://apps.who.int/trialsearch/>). We will contact the authors to get further information on ongoing or unpublished studies, if necessary. In order to ensure that the search is comprehensive, we will look through the bibliography of the included studies or reviews to identify the relevant reports. Grey literature (including reports and conference presentations) will be searched through Google Scholar and other relevant websites.

Study records {#s3c}
-------------

### Data management {#s3c1}

All previously searched literature will be imported into EndNote V.X8 software (Clarivate Analytics, Philadelphia, PA, USA), and duplicates will be removed. The titles and abstracts obtained from the previous searches will be inspected independently by two investigators (WL and XY). If the article meets the eligibility criteria, or if there is any uncertainty about including a particular study, the report will be downloaded.

### Selection process {#s3c2}

The imported articles will be screened by two independent investigators (WL and XY) to determine whether they meet the criteria for inclusion. We will ask the authors for additional information when necessary. Reasons for excluding studies will be recorded. The two investigators will resolve any disagreements through discussion, and the third investigator (LQ) will offer advice when agreement cannot be reached.

### Data collection process {#s3c3}

Two investigators (BP and YT) will independently extract data using a standardised data collection form. The extracted data will include: (1) study characteristics such as first author, journal, year and study design; (2) patients' characteristics including the number of patients in each group, age, sex, BMI and severity of OHS; (3) intervention characteristics (type of PAP therapy, mode of bilevel therapy, inspiratory PAP, expiratory PAP and back-up rate), mean daily use of ventilation and treatment duration; and (4) primary and secondary outcomes as described above. For crossover trials, we will only extract the data from the first phase, primarily because of the carry-over effect. When the extraction process is complete, we will merge the two collections into one for further analysis. Should there be any disagreements at this stage, the two investigators will reach an agreement through discussion. If agreement cannot be reached, the third investigator (LQ) will participate in the discussion to reach a final conclusion.

Risk of bias in individual studies {#s3d}
----------------------------------

Two investigators (YQ and JW) will use the Cochrane Collaboration's tool to assess the risk of bias of the included studies.[@R24] Six domains will be assessed: selection bias, performance bias, detection bias, attrition bias, reporting bias and 'other' bias. Each domain will be judged as 'low risk', 'unclear risk' or 'high risk'. The support for these judgements will be clarified in a risk of bias table. Divergences will be discussed first by the two investigators, and if an agreement cannot be reached, the third investigator (LQ) will provide a suggestion.

Data synthesis {#s3e}
--------------

Analyses will be done using RevMan V.5.3.5 software (Cochrane, London, UK).

### Measures of treatment effect {#s3e1}

For continuous outcomes such as PaCO~2~, 6 min walk distance, and so on, the weighted mean difference or standardised mean difference with 95% CIs will be used. Dichotomous outcomes such as patient mortality and the incidence of hospital readmission will be described using the risk ratio with 95% CIs.

### Dealing with missing data {#s3e2}

When data are missing or inapplicable, we will contact the original authors by email or use a formula to convert them into available data.[@R24] If the missing data cannot be obtained, we will follow the recommendations of the Cochrane Handbook for Systematic Reviews of Intervention[@R24]: (1) make precise the hypothesis of any methods used to handle the missing data; (2) sensitivity analyses will be used to assess how sensitive results are to reasonable changes in the assumptions that are made; (3) consider the potential effect of the missing data as limitations in our study.

### Assessment of heterogeneity {#s3e3}

We will investigate statistical heterogeneity among the included studies using the Q statistic and I^2^ index. A p value of ≤0.10 for the Q statistic will be considered to be statistically significant heterogeneity. I^2^ values \<25%, 25%--50% or \>50% represent low, moderate or high heterogeneity, respectively. We will apply a fixed effects model if no heterogeneity exists. When substantial heterogeneity (I^2^\>50% or p≤0.1) is detected, we will try to identify the source of heterogeneity by subgroup analysis, sensitivity analysis or using a random effects model. If substantial heterogeneity cannot be well explained, we will not proceed with the meta-analysis and a descriptive, qualitative summary will be made.[@R24]

### Additional analyses {#s3e4}

Possible sources of heterogeneity will be determined through carrying out subgroup analysis based on gender, BMI, the baseline presentation of the patient (acute decompensation or during clinical stability), the severity of the OHS (mild (PaCO~2~ 46--60 mm Hg), moderate (PaCO~2~ 60--80 mm Hg) or severe (PaCO~2~ ≥80 mm Hg)),[@R28] whether combined with obstructive sleep apnoea, the mode of bilevel therapy, the mean daily home use of the ventilator and the duration of the follow-up periods (short term (\<3 months) or long term (≥3 months)). Sensitivity analysis will also be performed to detect the source of heterogeneity. When substantial heterogeneity exists, we will exclude the study and compare its impact on the pooled estimate. If we find the source of heterogeneity, we will review the literature again to evaluate its quality and bias and decide whether the particular study is to be retained or excluded. If the study is excluded, the reasons for its removal will be explained in the discussion. If the quantitative synthesis is not appropriate, a narrative method will be used. This approach will present the information in a text or table in order to interpret and summarise the features and outcomes among the included studies.

Metabiases {#s3f}
----------

Publication bias will be assessed through the funnel plot if the number of the included studies is ≥10. In addition, in order to assess the reporting bias, we will search the database of the registered protocols mentioned above to confirm whether the study's prespecified outcomes have not been reported.

Confidence in cumulative estimate {#s3g}
---------------------------------

The Grading of Recommendations Assessment, Development and Evaluation system will be used for rating the quality of evidence for all outcomes of the included studies. The quality of evidence will be classified into four levels of quality (high, moderate, low and very low). Because RCTs are considered to be high quality, the quality of the evidence may be downgraded when study limitations, inconsistency of results, indirectness of evidence, imprecision or reporting bias occurs.[@R29]

Patient and public involvement statement {#s3h}
----------------------------------------

Patients and public were not involved in this manuscript.

Discussion {#s4}
==========

PAP therapy is considered as the first-line treatment for patients with OHS. However, the optimal mode of PAP therapy is still not clear. To the best of our knowledge, this is the first systematic review and meta-analysis to undertake a comparison between domiciliary bilevel and CPAP therapy for patients with OHS. Therefore, the findings will aid clinicians in choosing the most appropriate long-term home therapy for these individuals.

Bilevel therapy can be delivered as S, T, S/T or VAPS mode.[@R31] In S mode, ventilator will only be triggered when it detects a pressure or flow change by the inspiratory effort of the patient. In this mode, inspiratory trigger failure may occur due to excessive leakage or from the emergence of central apnoea, leading to poor nocturnal gas exchange and sleep quality.[@R32] With the T mode, all breaths are triggered by the ventilator only which can produce patient/ventilator asynchrony and patient discomfort. The S/T mode allows the patient to trigger the device to initiate inspiratory support, but if the patient's spontaneous respiratory rate drops below the back-up rate set by the clinician, then the ventilator will trigger the breath. This may reduce the rate of patient/ventilator asynchrony, relieve inspiratory effort and provide better gas exchange if the back-up rate is set high enough.[@R32] VAPS mode, a mixed mode of bilevel therapy, automatically adjusts the inspiratory pressure level within a preset pressure range in order to maintain a clinician-set target tidal volume. With the VAPS mode, it can adapt to variations in ventilatory need created by changes in body position, sleep stage or lung mechanics.[@R34] Hence, subgroup analysis will be performed to find out which modes of bilevel therapy provide better outcomes for patients with OHS.

Ethics and dissemination {#s4a}
------------------------

Our findings will be submitted to a peer-reviewed journal for publication.
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